EW
DNTH icon

Evoke Wealth’s Dianthus Therapeutics DNTH Stock Holding History

Evoke Wealth’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,131
Closed -$131K – 1199
2021
Q3 		$131K Hold
1,131
– – ﹤0.01% 392
2021
Q2 		$177K Hold
1,131
– – 0.01% 372
2021
Q1 		$214K Hold
1,131
– – 0.01% 298
2020
Q4 		$142K Hold
1,131
– – 0.01% 266
2020
Q3 		$123K Hold
1,131
– – 0.01% 257
2020
Q2 		$136K Hold
1,131
– – 0.01% 236
2020
Q1 		$114K Hold
1,131
– – 0.02% 246
2019
Q4 		$274K Hold
1,131
– – 0.03% 186
2019
Q3 		$186K Buy
+1,131
New +$215K 0.02% 270

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Evoke Wealth's DNTH Position: Q4 2021 in Review

Evoke Wealth sold out of Dianthus Therapeutics (DNTH) in Q4 2021, closing a stake of 1,131 shares — an estimated $131K sold.

Evoke Wealth first reported a position in DNTH in Q3 2019 and held it in 9 quarters. The position peaked at $274K in Q4 2019. 94 funds tracked by Wall St. Rank hold DNTH as of Q4 2021.

  • Evoke Wealth reported no remaining Dianthus Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Evoke Wealth sold 1,131 Dianthus Therapeutics shares in Q4 2021, an estimated $131K.
  • Evoke Wealth first reported a position in Dianthus Therapeutics in Q3 2019 and held it in 9 quarters.
  • Evoke Wealth's Dianthus Therapeutics position peaked at $274K in Q4 2019.
  • 94 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2021.

Based on Evoke Wealth's 13F filing for Q4 2021, filed 9 Feb 2022.